📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-08-19 11:57
343 analysed today
343
Today
133,232
All-time analysed
40,094
Positive
6,279
Negative
79,048
Neutral
7,743
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
31 announcements match the current filters (relevance ≥ 5).
Rubicon Q1 FY27 Call: Revenue Rises 52% YoY to ₹534.3 Cr, PAT Surges 96% to ₹84.8 Cr
Rubicon Research reported a 52% YoY jump in Q1 FY27 revenue from operations to ₹534.3 crore (INR 5,343 million), driven by strong demand and specialty portfolio expansion. Operating EBITDA grew 63.2% YoY to ₹129.1 crore with margins at 24.2%, while PAT surged 96% YoY to ₹84.8 crore (partially aided by a one-off insurance claim). The newly consolidated Arinna acquisition added ₹12 crore to revenue with neutral EBITDA impact. Specialty products contributed 36% of gross profit, and ROCE remained robust at 36% despite ~25% of capital employed in pre-revenue assets.
Confidence: HIGH
What changedSubmission of the detailed transcript for the Q1 FY27 earnings call held on August 14, 2026, covering operational performance, gross margin optimization, and site operational updates.
Why it mattersClarifies management strategy of prioritizing higher-margin specialty products over low-margin outsourced volume, and outlines growth runway from the Pithampur facility.
Q1 FY27 Revenue: ₹534.3 crYoY Revenue Growth: 52%Operating EBITDA Margin: 24.2%Q1 FY27 PAT: ₹84.8 crSpecialty Share of Gross Profit: 36%
📅 Short termSequential traction in US dollar revenues expected to recover in Q2 FY27 after tactical gross margin corrections and GST refund normalization.
📈 Long termOperationalization of the 30-acre Pithampur site and scaling of the specialty pipeline provide multi-year capacity headroom and operating leverage.
⚠ Risk flags
- Pending US FDA EIR clearance for the Pithampur manufacturing plant
- Temporary reliance on contract manufacturers impacting margin upside until internal capacity ramps up
Key Highlights
Revenue from operations grew 52% YoY to ₹534.3 crore; USD revenues grew 32% YoY to $55 million
PAT increased 96% YoY to ₹84.8 crore with quarterly EPS reaching ₹5.08
Gross margin improved sequentially by ~140 bps to 67.7%, driven by selective shedding of lower-margin contracts
Pithampur plant has ~₹150 crore capital invested; EIR is awaited and commercial ramp-up is targeted over the next 9-12 months
👀 What to Watch
Track the receipt of the US FDA EIR and subsequent commercialization timeline for the Pithampur facility over the next 2-3 quarters, alongside normalization of operating cash flows.
Rubicon Research Appoints Rohit Saraogi as CFO; Nitin Jajodia Transitions to CCO Role
Rubicon Research has announced a leadership transition effective August 14, 2026, appointing Rohit Saraogi as CFO-Designate. The current CFO, Nitin Jajodia, will transition to a business-focused role as Chief Commercial Officer (CCO) to support the company's next growth phase. Additionally, the tenure of Chairman Venkat Changavalli has been extended until June 10, 2027. These changes come as the company targets a 25-39% growth rate and prepares to ramp up its newly acquired Pithampur facility.
Confidence: HIGH
What changedThe company has split the financial and commercial leadership roles by appointing a new CFO and moving the existing CFO to a Chief Commercial Officer position.
Why it mattersA dedicated CCO role suggests a heightened focus on commercializing the company's 82 approved products and managing the US market expansion, while a new CFO with MNC experience may enhance capital allocation and digital finance transformation.
New CFO Experience: 24 yearsChairman Extension End Date: June 10, 2027Dec 2025 Revenue: ₹475.53 crDec 2025 Net Profit: ₹72.80 crPromoter Holding: 59.76%
📅 Short termThe management change is likely to be viewed as a routine organizational strengthening; no immediate impact on stock price is expected.
📈 Long termThe transition of the former CFO to a commercial role could improve operational efficiency and market penetration, supporting the company's long-term goal of scaling its specialty product portfolio.
⚠ Risk flags
- Execution risk during leadership transition
- Dependency on US market for near-term growth
Key Highlights
Rohit Saraogi appointed as CFO-Designate effective August 14, 2026, with over 24 years of experience in MNCs like Diageo and Coca-Cola.
Current CFO Nitin Jajodia to move into an operating role as Chief Commercial Officer (CCO).
Chairman Venkat Changavalli's term extended from September 18, 2026, to June 10, 2027.
Company reported a net profit of ₹72.80 cr on revenue of ₹475.53 cr in the Dec 2025 quarter.
Management transition aims to support a projected growth rate of 25-39% and a 93% product commercialization rate.
👀 What to Watch
Investors should monitor the transition's impact on financial reporting and the execution of the Pithampur facility ramp-up, which is critical for reducing outsourcing costs.
51.6% Revenue Growth in Q1 FY27; Rubicon Acquires First US Manufacturing Site
Rubicon Research reported a robust Q1 FY27 with revenue growing 51.6% YoY to ₹534.3 crore and PAT nearly doubling to ₹84.8 crore. The company successfully integrated the ₹175.9 crore Arinna Lifesciences acquisition and secured its first US manufacturing footprint via the $2.9 million acquisition of InvaTech Pharma. Gross margins improved to 67.7% as the company tactically reduced low-margin outsourced business to manage capacity constraints. Management maintained a high pre-tax ROACE of 36% despite significant capital being locked in pre-revenue assets.
Confidence: HIGH
What changedRubicon has established its first physical manufacturing presence in the US and significantly expanded its Indian branded formulation business through the Arinna acquisition.
Why it mattersThe US facility allows Rubicon to bid for US government contracts and improves supply chain agility for high-value specialty products. Strong financial performance despite capacity constraints validates the company's shift toward a high-margin specialty generic model.
Q1 Revenue Growth (YoY): 51.6%Q1 PAT Growth (YoY): 95.8%Arinna Acquisition Value: ₹1,759 MnInvaTech Acquisition (USD): $2.9 MnAnnualized Pre-tax ROACE: 36%Net Working Capital Days: 114 days
📅 Short termThe stock is likely to react positively to the nearly 100% PAT growth and the strategic entry into US manufacturing.
📈 Long termThe transition to a vertically integrated specialty player with manufacturing bases in both India and the US provides a structural runway for 25-39% growth as guided.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Continued reliance on third-party CMOs until mid-2026
- Regulatory risks at the newly acquired InvaTech site (6 procedural Form 483 observations in May 2026)
- Geopolitical impact on key input costs
Key Highlights
Revenue from operations increased 51.6% YoY to ₹5,343 million in Q1 FY27.
PAT grew 95.8% YoY to ₹848 million, with fully diluted EPS rising to ₹5.08.
Acquired InvaTech Pharma's US facility for an enterprise value of $2.9 million in July 2026.
Specialty portfolio contribution to gross profit reached 36% in Q1 FY27.
Capital employed in pre-revenue or recently acquired assets (Pithampur, Arinna, NJ) stands at ₹3,537 million.
👀 What to Watch
Monitor the operationalization timeline of the Pithampur and New Jersey facilities in CY2027, which are key to reducing outsourcing costs. Investors should also track the margin impact of the new ESOP scheme and Arinna growth-enabler costs in the coming quarters.
51.6% Revenue Growth in Q1 FY27; Rubicon Acquires US Facility for $2.9 Million
Rubicon Research reported a strong Q1 FY27 with revenue growing 51.6% YoY to ₹534.3 cr and PAT nearly doubling to ₹84.8 cr. The company successfully consolidated the ₹175.9 cr Arinna Lifesciences acquisition and completed the $2.9 million purchase of InvaTech Pharma, marking its first US manufacturing footprint. Gross margins improved to 67.7% as the company tactically shifted away from lower-margin business to manage capacity constraints. Management is targeting CY2027 for operationalizing new sites in Pithampur and New Jersey to reduce reliance on third-party outsourcing.
Confidence: HIGH
What changedRubicon has established its first US-based manufacturing presence through the InvaTech acquisition and entered the domestic branded formulations market via Arinna Lifesciences.
Why it mattersThe shift toward own-manufacturing and specialty products (36% of GP) reduces dependency on third-party CMOs and improves pricing power in the US market, which remains the company's primary revenue driver.
Q1 Revenue Growth (YoY): 51.6%Q1 PAT Growth (YoY): 95.8%InvaTech Acquisition Value: $2.9 millionArinna Acquisition Value: ₹1,759 millionGross Margin: 67.7%Annualized Pre-tax ROACE: 36%
📅 Short termThe stock may react positively to the strong bottom-line growth and successful integration of recent acquisitions, alongside stable pricing in the US specialty segment.
📈 Long termThe transition to a vertically integrated specialty pharma player with manufacturing bases in India and the US provides a structural runway for 25-39% growth as guided by management.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Reliance on US market for majority of revenue
- Integration risks of multiple simultaneous acquisitions
- Pre-revenue costs at new sites may temporarily weigh on EBITDA
Key Highlights
Revenue from operations increased 51.6% YoY to ₹5,343 million in Q1 FY27.
PAT surged 95.8% YoY to ₹848 million, with diluted EPS rising to ₹5.08 from ₹2.79.
Acquired InvaTech Pharma (USA) for $2.9 million, adding a USFDA-inspected facility for oral solids and liquids.
Specialty portfolio contribution to Gross Profit reached 36% in Q1 FY27, up from 32.5% in H1 FY26.
Consolidated Arinna Lifesciences following a ₹1,759 million acquisition, adding 160 sales reps and 60 CNS brands.
👀 What to Watch
Monitor the execution timeline for the Pithampur and New Jersey facilities, both expected to commence manufacturing in CY2027, which is critical for margin expansion and reducing outsourcing costs.
95.8% YoY PAT Growth; Rubicon Reports ₹84.8 Cr Profit in Q1 FY27 with New Acquisitions
Rubicon Research delivered a robust Q1 FY27 performance, with consolidated revenue growing 51.6% YoY to ₹534.34 cr and PAT surging 95.8% YoY to ₹84.78 cr. The results are bolstered by the integration of Arinna Lifesciences (85% stake acquired for ₹175.92 cr in April 2026). The company continues its aggressive expansion, acquiring a New Jersey manufacturing facility for USD 2.9 million post-quarter. R&D remains a priority, with ₹60.07 cr (11.2% of revenue) invested during the quarter.
Confidence: HIGH
What changedRubicon has significantly expanded its consolidated footprint through the acquisition of Arinna Lifesciences and a new US-based manufacturing site, while maintaining strong double-digit growth.
Why it mattersThe aggressive M&A activity and US capacity expansion are critical for Rubicon's strategy to reduce outsourcing costs and grow its branded/specialty portfolio, which currently faces lower competitive pressure.
Consolidated Revenue (Q1 FY27): ₹534.34 crConsolidated PAT (Q1 FY27): ₹84.78 crArinna Lifesciences Acquisition Cost: ₹175.92 crUS Facility Enterprise Value: USD 2.9 millionUnutilized IPO Proceeds: ₹80.57 crR&D Spend as % of Revenue: 11.2%
📅 Short termThe stock is likely to react positively to the strong profit growth and the clear execution of its inorganic growth strategy.
📈 Long termStructural growth is supported by a shift toward specialty products (32.5% of GP) and the transition from outsourcing to in-house manufacturing at Pithampur and the US.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Integration risks of multiple simultaneous acquisitions
- High dependency on US market regulatory approvals
- Potential margin pressure until new facilities reach full capacity
Key Highlights
Consolidated revenue from operations grew 51.6% YoY to ₹534.34 cr.
Net profit (PAT) increased 95.8% YoY to ₹84.78 cr from ₹43.30 cr in the year-ago period.
Completed the acquisition of an 85% stake in Arinna Lifesciences for ₹175.92 cr on April 30, 2026.
Post-quarter acquisition of a manufacturing facility in New Jersey, USA, for an enterprise value of USD 2.9 million.
R&D revenue expenditure for the quarter stood at ₹60.07 cr, representing 11.2% of consolidated revenue.
👀 What to Watch
Monitor the margin impact as the company integrates Arinna Lifesciences and operationalizes the new New Jersey facility. Watch for the completion of the Kia Health Tech merger and the scheduled ramp-up of the Pithampur plant by Q1 CY2027.
₹1.50 Final Dividend: Rubicon Research Sets August 7 as Record Date for FY26
Rubicon Research has issued a detailed communication regarding the tax deduction at source (TDS) for its recommended final dividend of ₹1.50 per equity share for FY 2025-26. The dividend is subject to shareholder approval at the upcoming Annual General Meeting (AGM) scheduled for August 26, 2026. The company has fixed August 7, 2026, as the record date to determine eligible shareholders. Tax will be deducted at 10% for resident individuals with a valid PAN (if dividend exceeds ₹10,000) and 20% for those without a valid PAN.
Confidence: HIGH
What changedThe company has formalized the administrative process, record date, and tax deduction guidelines for the FY26 final dividend payment.
Why it mattersThis is a routine but necessary procedure for the distribution of profits to shareholders, ensuring compliance with the Income Tax Act, 2025.
Final Dividend: ₹1.50 per shareRecord Date: August 7, 2026AGM Date: August 26, 2026TDS Rate (Resident with PAN): 10%Document Submission Deadline: August 10, 2026
📅 Short termThe stock may see minor price adjustments around the ex-dividend date (typically one day before the record date).
📈 Long termLimited; this is a routine administrative filing related to profit distribution and does not impact the company's structural growth outlook.
Key Highlights
Recommended a final dividend of ₹1.50 per equity share for the financial year ended March 31, 2026.
Fixed Friday, August 7, 2026, as the Record Date for determining shareholder eligibility.
Standard TDS rate of 10% for resident individuals with PAN; 20% for those without PAN or Aadhaar linkage.
Deadline for submitting tax-related documents (Form 121/41) is Monday, August 10, 2026.
The 27th Annual General Meeting (AGM) to approve the dividend is scheduled for August 26, 2026.
👀 What to Watch
Eligible shareholders should ensure their PAN and bank account details are updated with their Depository Participant before August 7, 2026, to ensure correct tax treatment and timely credit.
USD 2.9M Acquisition of First US Manufacturing Facility in New Jersey
Rubicon Research has acquired its first US-based manufacturing facility in East Brunswick, NJ, for USD 2.9 million (~Rs 24.3 cr) through a bankruptcy court process. The site, comparable in size to the company's Satara facility, produces oral solid and liquid formulations and is adjacent to Rubicon's existing US distribution center. While a May 2026 USFDA inspection resulted in 6 procedural observations, the company expects a timely resolution. Production is scheduled to commence in CY 2027 following quality system integration and further capital investment over 3 years.
Confidence: HIGH
What changedRubicon transitioned from an India-only manufacturer to having a direct production footprint in its largest market, the USA.
Why it mattersThis provides supply chain resilience, proximity to customers, and eligibility for US government contracts, supporting the company's 25-39% growth target.
Enterprise Value: USD 2.9 millionAcquisition vs Dec 2025 Revenue: ~5.1%USFDA Observations: 6Operational Commencement: CY 2027R&D Scientists: 200+
📅 Short termThe market is likely to view the low-cost entry into US manufacturing favorably, though production is months away.
📈 Long termSignificant for scaling the specialty and branded portfolio (currently 32.5% of GP) and improving US market agility.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- USFDA regulatory clearance of pending observations
- Execution of US-based manufacturing
- Future capex requirements
Key Highlights
Acquisition of NJ facility at an enterprise value of USD 2.9 million
Facility size is approximately the same as the company's Satara plant in India
USFDA May 2026 inspection issued a Form 483 with 6 procedural observations
Manufacturing operations expected to start in Calendar Year 2027
Strategic proximity to the company's AimRx distribution center in the US
👀 What to Watch
Watch for the formal USFDA clearance of the May 2026 observations and updates on the 3-year capital investment plan for the site.
₹1.50 Final Dividend: Rubicon Sets Aug 7 Record Date; Approves Subsidiary Merger
Rubicon Research has fixed August 7, 2026, as the record date for a final dividend of ₹1.50 per equity share for FY 2025-26. The Board also approved the formal Scheme of Merger for its wholly-owned subsidiary, Kia Health Tech Private Limited, with an appointed date of April 1, 2026. Since the merger involves a 100% subsidiary, no new shares will be issued, resulting in zero equity dilution. The dividend payment remains subject to shareholder approval at the upcoming AGM on August 26, 2026.
Confidence: HIGH
What changedThe company has finalized the timeline for its FY26 dividend distribution and approved the legal scheme for merging its wholly-owned subsidiary.
Why it mattersThe dividend confirms the company's ability to return cash to shareholders, while the merger simplifies the corporate structure without impacting the shareholding pattern.
Final Dividend: ₹1.50 per shareFace Value: ₹1.00Record Date: August 7, 2026Dividend Yield: ~0.1%Appointed Date for Merger: April 1, 2026
📅 Short termThe stock may see minor price adjustments around the ex-dividend date; the merger update is administrative and unlikely to drive significant price action.
📈 Long termLimited structural impact from the merger; long-term value depends on the ramp-up of specialty products which currently contribute 32.5% to gross profit.
Key Highlights
Final dividend of ₹1.50 per equity share (150% of face value) recommended for FY26.
Record date for dividend eligibility fixed as Friday, August 7, 2026.
Merger of Kia Health Tech Private Limited approved with an appointed date of April 1, 2026.
27th Annual General Meeting (AGM) to be held on August 26, 2026.
Dividend yield stands at approximately 0.1% based on the current price of ₹1511.8.
👀 What to Watch
Investors should ensure shares are held before the ex-dividend date to qualify for the ₹1.50 payout and monitor the operationalization of the Pithampur facility by mid-CY2026 for growth triggers.
Rubicon Research Sets Aug 7 Record Date for ₹1.50 Dividend; Approves WOS Merger
Rubicon Research has finalized August 7, 2026, as the record date for its final dividend of ₹1.50 per share for FY25-26. The Board also approved the formal Scheme of Merger for its wholly-owned subsidiary, Kia Health Tech Private Limited, with an appointed date of April 1, 2026. As the entity is a 100% subsidiary, no new shares will be issued, and there will be no change in the company's shareholding pattern. The 27th Annual General Meeting is scheduled for August 26, 2026, to seek shareholder approval for these items.
Confidence: HIGH
What changedThe company has formalized the timeline for its FY26 dividend payout and approved the legal scheme for merging its subsidiary, Kia Health Tech.
Why it mattersThe merger simplifies the corporate structure and reduces administrative overhead, while the dividend confirms the distribution of profits to shareholders following a period of strong growth.
Final Dividend: ₹1.50 per shareDividend Record Date: August 7, 2026Merger Appointed Date: April 1, 2026AGM Date: August 26, 2026Face Value: ₹1.00
📅 Short termThe stock may see routine price adjustments around the ex-dividend date; the merger is administrative and unlikely to cause significant price volatility.
📈 Long termStructural simplification through subsidiary mergers is a positive step for operational efficiency, though the primary long-term driver remains the specialty product pipeline.
Key Highlights
Final dividend of ₹1.50 per equity share (150% of face value ₹1) recommended for FY25-26.
Record date for dividend eligibility fixed as Friday, August 7, 2026.
Merger of Kia Health Tech Private Limited (WOS) approved with an appointed date of April 1, 2026.
27th Annual General Meeting (AGM) to be held on August 26, 2026.
Zero share issuance or dilution resulting from the merger of the wholly-owned subsidiary.
👀 What to Watch
Investors should note the August 7 record date for dividend eligibility and monitor the progress of the Pithampur facility ramp-up, which is expected to be operational by mid-CY2026.
2 US FDA Observations for Pithampur Facility; Commercial Ramp-up Targeted for Q1 CY2027
Rubicon Research has concluded its first US FDA inspection of the Pithampur facility, which was acquired in June 2025 for ₹149 crore. The unannounced inspection, conducted from June 29 to July 3, 2026, resulted in a Form 483 with two procedural observations. Management has clarified that these observations do not relate to data integrity and expects a timely resolution. The company remains on track to ramp up commercial operations at this site by Q1 CY2027, a key milestone for internalizing production and improving gross margins.
Confidence: HIGH
What changedThe newly acquired Pithampur manufacturing facility has undergone its first US FDA audit, a necessary regulatory step before full-scale commercialization.
Why it mattersThis facility is essential for Rubicon to reduce its reliance on third-party manufacturers (CMOs), which currently caps gross margins at 68%. Successful operationalization is key to achieving the company's specialty-led growth strategy.
Observations issued: 2Acquisition cost of facility: ₹149 croreTargeted ramp-up date: Q1 CY2027Commercialization rate: 93%Latest Quarterly Revenue (Dec 2025): ₹475.53 cr
📅 Short termThe stock may see some volatility due to the Form 483 issuance, though the procedural nature of the observations typically suggests a lower risk of escalation.
📈 Long termIf cleared, the Pithampur plant will provide the necessary capacity to support Rubicon's robust pipeline of specialty products, which already contribute 32.5% to gross profit.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Regulatory delay in EIR issuance
- Potential for observations to be upgraded upon further review
- High dependency on US market approvals
Key Highlights
US FDA inspection conducted over 5 days from June 29 to July 3, 2026.
Form 483 issued with 2 procedural observations, with no data integrity concerns reported.
Facility was acquired in June 2025 for ₹149 crore to alleviate capacity constraints.
Commercial operations at the Pithampur plant are guided to ramp up by Q1 CY2027.
Company maintains a high commercialization rate of 93%, with 76 out of 82 approved products commercialized.
👀 What to Watch
Investors should monitor the final classification of the inspection (NAI/VAI) and the issuance of the Establishment Inspection Report (EIR), as this facility is critical for the company's 25-39% growth guidance.
Rubicon Research Q4 FY26 PAT Jumps 111% YoY; Revenue Up 44% to INR 5,139 Million
Rubicon Research reported a stellar Q4 FY26 with revenue growing 44% YoY to INR 5,139 million and PAT surging 111% to INR 768 million. The full-year FY26 revenue reached INR 17,540 million, driven by a robust specialty portfolio and 12 new product approvals. While gross margins saw a slight dip due to increased reliance on outsourced manufacturing to meet high demand, EBITDA margins remained healthy at 23.1%. The company has a strong pipeline with 24 products under FDA review and expects the Pithampur facility to ramp up by Q1 CY2027.
Key Highlights
Q4 FY26 revenue grew 44% YoY to INR 5,139 million; PAT increased 111% to INR 768 million.
Full-year FY26 PAT stood at INR 2,467 million, representing a significant 84% growth over the previous year.
R&D productivity reached 5.9x for the FY26-FY23 period, with 24 products currently under US FDA review.
The Board recommended a 150% dividend (INR 1.5 per share) with a 10% payout ratio.
Specialty portfolio contributed 33% to the total gross profit for the quarter, reflecting a shift toward high-value products.
👀 What to Watch
Investors should monitor the Pithampur facility's FDA inspection and commercialization in early 2027, as it is key to improving gross margins by reducing outsourcing. The strong R&D productivity and robust pipeline suggest continued growth momentum, making it a strong 'Hold' or 'Accumulate' on dips.
Rubicon Research Recommends Final Dividend of ₹1.50 per Share for FY26
Rubicon Research Limited's Board of Directors has recommended a final dividend of ₹1.50 per equity share for the financial year ended March 31, 2026. This dividend is calculated on a face value of ₹1 per share, representing a 150% payout ratio relative to the face value. The announcement was made alongside the approval of the company's audited financial results for the quarter and full year. The final payout is subject to shareholder approval at the upcoming Annual General Meeting and will be distributed within 30 days of declaration.
Key Highlights
Recommended a final dividend of ₹1.50 per equity share for the financial year ended March 31, 2026
Dividend is based on a face value of ₹1.00 per share, reflecting a 150% dividend rate
Audited financial results for Q4 and FY26 approved with an unmodified opinion from Deloitte Haskins & Sells LLP
Dividend payment to be completed within 30 days from the date of declaration at the Annual General Meeting
👀 What to Watch
Investors should monitor for the announcement of the record date to ensure eligibility for the ₹1.50 per share dividend. The unmodified audit report provides additional assurance regarding the company's financial disclosures.
Rubicon Research Recommends ₹1.50 Dividend and Approves ESOP Scheme 2026
Rubicon Research Limited has approved its audited financial results for the quarter and year ended March 31, 2026, with an unmodified auditor's opinion. The Board has recommended a final dividend of ₹1.50 per equity share (150% of face value), pending shareholder approval at the upcoming AGM. Additionally, the company is moving forward with the 'Employees Stock Option Scheme 2026' to incentivize and retain talent across its global operations.
Key Highlights
Recommended a dividend of ₹1.50 per equity share of face value ₹1 for FY 2025-26.
Approved audited standalone and consolidated financial results for the full year ended March 31, 2026.
Statutory auditors Deloitte Haskins & Sells LLP issued a clean, unmodified opinion on the financial statements.
Formulated and adopted the 'Rubicon Research Limited - Employees Stock Option Scheme 2026'.
Consolidated results include performance from 13 global subsidiaries across the US, Canada, Singapore, and Europe.
👀 What to Watch
Investors should monitor the upcoming Annual General Meeting for dividend declaration and review the full financial statement for year-on-year growth metrics. The introduction of the ESOP scheme is a positive indicator of management's focus on long-term human capital stability.
Rubicon Research Q4 PAT Surges 112% to ₹76.8 Cr; Revenue Up 43.5% YoY
Rubicon Research reported robust Q4 FY26 results with revenue growing 43.5% YoY to ₹513.9 crore and PAT doubling to ₹76.8 crore. The company maintained strong EBITDA margins of 23.6% despite increased reliance on outsourced manufacturing due to capacity constraints. Significant progress was made in debt reduction using IPO proceeds, and the acquisition of Arinna Lifesciences marks a strategic entry into the Indian CNS market. With 24 products under USFDA review and 12 approvals received in FY26, the growth trajectory remains strong.
Key Highlights
Q4 FY26 Revenue grew 43.5% YoY to ₹5,139 million; PAT surged 111.8% to ₹768 million.
Full-year FY26 Revenue reached ₹17,540 million with an 83.6% growth in PAT to ₹2,467 million.
Board recommended a 150% dividend (₹1.50 per share) for the financial year.
Utilized IPO proceeds to repay ₹265 crore of debt, improving the debt-to-equity profile.
Acquired 85% stake in Arinna Lifesciences for ₹176 crore to establish a domestic CNS market presence.
👀 What to Watch
The company shows high R&D productivity (5.9x revenue multiple) and a strong product pipeline, making it a compelling growth story. Investors should monitor the Pithampur facility's USFDA inspection as its ramp-up in Q1 CY27 is expected to be margin accretive.
Rubicon Research Recommends INR 1.50 Dividend and Approves Audited FY26 Financial Results
Rubicon Research Limited has approved its audited standalone and consolidated financial results for the quarter and fiscal year ended March 31, 2026. The Board of Directors recommended a final dividend of INR 1.50 per equity share (150% of face value), pending shareholder approval at the upcoming AGM. Statutory auditors Deloitte Haskins & Sells LLP have issued an unmodified opinion on the financial statements, indicating a clean audit. The consolidated results incorporate performance from various global subsidiaries across North America, Europe, and Asia-Pacific.
Key Highlights
Recommended a dividend of INR 1.50 per equity share of face value INR 1/- for the financial year ended March 31, 2026.
Approved audited standalone and consolidated financial results for the quarter and year ended March 31, 2026.
Statutory auditors issued an unmodified opinion, confirming the reliability of the financial disclosures.
Dividend payment is scheduled to be completed within 30 days of declaration by members at the AGM.
Consolidated entities include major subsidiaries such as AdvaGen Pharma Limited and Validus Pharmaceutical LLC.
👀 What to Watch
Investors should monitor the detailed financial performance metrics once the full statement is available to assess year-on-year growth. The dividend recommendation offers a steady yield, but the focus should remain on the operational performance of its international pharmaceutical subsidiaries.
Rubicon Research Completes Acquisition of 85% Stake in Arinna Lifesciences
Rubicon Research Limited has successfully completed the secondary acquisition of an 85% stake in Arinna Lifesciences Limited as of April 30, 2026. This transaction follows the initial agreement announced on April 15, 2026, and was executed under the terms of a Share Purchase Agreement. Consequently, Arinna Lifesciences has now become a subsidiary of Rubicon Research. This strategic move is expected to expand Rubicon's footprint and product portfolio in the pharmaceutical and life sciences sector.
Key Highlights
Completed the acquisition of an 85% majority stake in Arinna Lifesciences Limited.
Arinna Lifesciences Limited has officially become a subsidiary of the company as of April 30, 2026.
The acquisition was a secondary purchase following a Share Purchase Agreement dated April 15, 2026.
👀 What to Watch
Investors should view this as a significant expansion move and monitor the upcoming quarterly results for the financial impact and synergy benefits of this acquisition.
Rubicon Research R&D Facility in Canada Clears USFDA Inspection with Zero Observations
Rubicon Research Limited has successfully completed a USFDA inspection at its R&D facility in Concord, Ontario, Canada. The unannounced inspection, which took place from April 20 to April 24, 2026, concluded with zero Form-483 observations. This outcome signifies full compliance with US regulatory standards and validates the company's quality management systems. For a research-driven pharmaceutical company, such a clean report is critical for maintaining its product development pipeline for the US market.
Key Highlights
USFDA conducted an unannounced inspection at the Concord, Canada R&D facility from April 20 to April 24, 2026.
The inspection concluded with zero Form-483 observations, indicating no regulatory non-compliance.
Successful audit ensures the facility can continue to support US-bound product development and filings.
This outcome reinforces Rubicon's commitment to maintaining high-quality standards in its global operations.
👀 What to Watch
Investors should view this as a significant positive development that mitigates regulatory risk for the company's R&D pipeline. The zero-observation report reflects strong operational quality, supporting a long-term positive outlook on the stock.
Rubicon Research Receives ₹17.25 Crore Income Tax Demand for AY 2023-24
Rubicon Research Limited has received an assessment order from the Income Tax Department for the Assessment Year 2023-24. The order includes additions and disallowances totaling ₹20.68 crore, primarily related to Arm's Length Pricing adjustments on international transactions. This has resulted in a total tax demand of ₹17.25 crore. The company has also been issued a show-cause notice for penalty proceedings but intends to contest the demand through an appeal, asserting a strong legal position.
Key Highlights
Total tax demand of ₹17.25 crore raised by the Income Tax Department for AY 2023-24.
Additions of ₹20.68 crore made due to Arm's Length Pricing adjustments on international transactions.
Show-cause notice issued for initiation of penalty proceedings under Section 270A.
Company is in the process of filing an appeal and remains confident in its legal merits.
The order was received on April 21, 2026, from the Assessment Unit, Mumbai.
👀 What to Watch
Investors should monitor the progress of the tax appeal as a negative outcome would result in a cash outflow of ₹17.25 crore plus potential penalties. While tax disputes are common for companies with international operations, the size of the demand warrants attention.
Rubicon Research Acquires 85% Stake in Arinna Lifesciences for INR 175.92 Crores
Rubicon Research has announced the acquisition of an 85% equity stake in Arinna Lifesciences, marking its entry into the Indian domestic CNS formulations market. The transaction values Arinna at an enterprise value of INR 200 Crores, with Rubicon paying approximately INR 175.92 Crores for the majority stake. Arinna is a specialist in Central Nervous System (CNS) therapies with over 60 brands and a network of 4,000+ prescribers. For the nine months ended December 2025, Arinna reported a provisional revenue of INR 56.7 Crores and an EBITDA of INR 9.5 Crores.
Key Highlights
Acquisition of 85% equity ownership in Arinna Lifesciences for a consideration of INR 175.92 Crores.
Arinna reported 9M FY26 provisional revenue of INR 56.7 Crores and EBITDA of INR 9.5 Crores.
The deal values Arinna at an Enterprise Value of INR 200 Crores on a cash and debt-free basis.
Strategic entry into the Indian CNS market with access to 60+ brands and 4,000+ prescribers.
Rubicon aims to leverage its R&D playbook which scaled its US revenues 32x between FY15 and FY25.
👀 What to Watch
Investors should look favorably on this acquisition as it diversifies Rubicon's revenue stream into the high-growth Indian domestic market. Monitor the successful integration of Arinna's distribution network with Rubicon's specialty product pipeline.
Rubicon Research to Acquire 85% Stake in Arinna Lifesciences for INR 175.92 Crores
Rubicon Research Limited has entered into definitive agreements to acquire an 85% stake in Arinna Lifesciences, an Ahmedabad-based branded pharmaceutical marketing firm. The acquisition is valued at an enterprise value of INR 200 Crores, with Rubicon paying approximately INR 175.92 Crores in cash. Arinna specializes in the CNS and neuro-psychiatric therapeutic segments and reported a turnover of INR 71.5 Crores for FY25. This strategic move is intended to provide Rubicon with a domestic sales and distribution network to launch its specialty products and drug-device combinations in India.
Key Highlights
Acquisition of 85% equity stake in Arinna Lifesciences for approximately INR 175.92 Crores.
Target company Arinna reported a turnover of INR 71.50 Crores in FY25, up from INR 60.06 Crores in FY23.
The transaction values Arinna at an enterprise value of INR 200 Crores on a cash and debt-free basis.
Strategic focus on the CNS (Central Nervous System) segment, leveraging Rubicon's IP and Arinna's distribution network.
The acquisition is expected to be completed within one month from the date of signing.
👀 What to Watch
This acquisition is a positive development as it provides Rubicon with a ready-made domestic platform to commercialize its CNS pipeline. Investors should monitor the integration and how this domestic presence impacts the company's overall margin profile.
